0.57
+5.03%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Rani Therapeutics Holdings
From its filings with the US Securities and Exchange Commission
Rani Therapeutics Holdings is based in San Jose, California and is incorporated in California. Its shares trade on Nasdaq under the ticker RANI. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $1.6m and a net loss of $29.7m. At that date it held total assets of $58.6m and shareholders' equity of $33.0m.
We are a clinical stage biotherapeutics company focusing on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. We are advancing a portfolio of oral therapeutics using our proprietary delivery technology and we are actively pursuing partnering the technology with third party biopharmaceutical companies for the oral delivery of their biologics and drugs.
Our technology comprises a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. We have two configurations of the platform – the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. We have completed three Phase 1 clinical trials using the RaniPill GO. We are also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC, which is intended to enable delivery of drug payloads up to 200µL in liquid form with high bioavailability. We have tested preclinically the RaniPill HC with multiple therapeutics, including multiple different antibodies and peptides. In December 2025, we initiated a Phase 1 clinical trial with RT-114, a RaniPill HC capsule containing a GLP-1/GLP-2 dual agonist (PG-102), for the treatment of obesity.
Quoted from its 10-K, filed 26 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 30 Jul 2021
- Employees
- 69
- Website
- ranitherapeutics.com ↗
- Head office
- 2051 RINGWOOD AVENUE, SAN JOSE, CA, 95131
- Incorporated in
- CA
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Leadership
Pay as last reported
- Mr. Mir ImranChairman of the Board, since 2021$223,245
- Mr. Talat ImranChief Executive Officer, Director, since 2014$3.0m
- Mr. Svai SanfordChief Financial Officer$1.3m
- Dr. Mir HashimChief Scientific Officer, since 2013$1.3m
- Mr. Eric GroenGeneral Counsel
- Ms. Kate MckinleyChief Business Officer
- Mr. Andrew FarquharsonDirector$205,745
- Dr. Dennis AusielloIndependent Director$207,745
- Mr. Jean-Luc ButelIndependent Director$214,495
- Dr. Maulik NanavatyIndependent Director$216,995
- Ms. Lisa RomettyIndependent Director$208,358
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- RaniPill capsule delivers large molecules like proteins and antibodies orally with high bioavailability.
- Rani Therapeutics has a clinical stage bio-therapeutics focus with five pipeline drugs including RT-101 for NETs treatment.
- San Jose facility manufactures RaniPill capsules enabling full control over production.
Weaknesses
- Rani Therapeutics has 69 employees which is below industry average for clinical stage biotech companies.
- The RaniPill GO delivers only up to three micrograms of drug dose limiting its application scope.
- RT-101 is the only pipeline drug with a specific indication for NETs and acromegaly treatment.
Opportunities
- Rani Therapeutics can expand RaniPill platform to deliver higher drug doses beyond three micrograms.
- The growing market for oral biologics delivery presents a significant opportunity for RaniPill technology.
- Rani Therapeutics can target additional diseases beyond NETs and acromegaly with its pipeline drugs.
Threats
- Rani Therapeutics faces competition from other oral delivery platforms in the pharmaceutical industry.
- The company's limited employee count of 69 may hinder its ability to scale rapidly.
- Regulatory approval delays could impact the timeline for RaniPill platform commercialization.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.